**Supplementary figure S2**

*Cellular Oncology*

# Inhibition of high level *E2F* in a *RB1* proficient *MYCN* overexpressing chicken retinoblastoma model normalizes neoplastic behaviour

Hanzhao Zhang (1), Dardan Konjusha (1), Nima Rafati (2,3), Tatsiana Tararuk (1) and Finn Hallböök (1)*

## Affiliations:

1. Department of Immunology, Genetics and Pathology, Uppsala University,

2. National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Uppsala University

3. Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden

* Corresponding author:

Finn Hallböök

Department of Immunology, Genetics and Pathology

Rudbeck laboratory, Uppsala University

751 85 Uppsala Sweden

Finn.Hallbook@igp.uu.se

**Fig. S2.** Expression profile from two patient-derived MYCNA tumours

Enriched GO terms based on DE genes from two patient-derived *MYCN*$^{A}$ tumours. **A** Top 20 enriched GO terms of downregulated DE genes of public available human dataset (https://www.ncbi.nlm.nih.gov/geo/, GSE161449). The comparison is patient-derived *MYCN*$^{A}$ *RB1* proficient retinoblastoma cell lines versus the same cell line with *MYCNOS1* silencing. **B** Top 20 enriched GO terms of upregulated DE genes of public available human dataset (https://www.biosino.org/node/index, OEP000103). The comparison is *MYCN*$^{A}$ *RB1* deficient retinoblastoma tumour versus para tumour tissue. **C** Top 20 enriched GO terms of downregulated DE genes of public available human dataset (https://www.biosino.org/node/index, OEP000103). The comparison is *MYCN*$^{A}$ *RB1* deficient retinoblastoma tumour versus para tumour tissue.



C Top 20 enriched GO terms of downregulated DE genes (OEP000103)